Target
IL6
3 abstracts
Abstract
Biomarkers in a phase 1b study of investigational microbiome therapeutic SER-155 in adults undergoing allogeneic hematopoietic cell transplantation (allo-HCT).Org: Memorial Sloan Kettering Cancer Center, Seres Therapeutics, University of Chicago, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Mayo Clinic,
Abstract
Biologic profile to predict overall survival in non-metastatic breast cancer: A latent class analysis on aging biomarkers.Org: Unité d'Oncogériatrie, Centre Hospitalier Lyon Sud and CarMeN laboratory of Lyon University, Pierre-Benite, France, Department of Oncology, AZ Sint-Jan, Brugge, Belgium, Department of General Medical Oncology Leuven Cancer Institute, University Hospitals Leuven, KU Leuven, Leuven, Belgium, Department of Surgical Oncology and Multidisciplinary Breast Centre, University Hospitals Leuven, Leuven, Belgium, Multidisciplinary Breast Center, University Hospitals Leuven – Campus Gasthuisberg, Leuven, Belgium,
Abstract
Tumor immune microenvironment (TIME) analysis of stage I lung adenocarcinoma with micropapillary pattern.Org: Shengjing Hospital of China Medical University, The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China,